1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Fate Therapeutics Inc (FATE)
  7. Quote


Fate Therapeutics Stock Price

-4.60 (-8.75%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 1,231,769
Bid Price 45.50
Ask Price 48.65
News -
Day High 53.02


52 Week Range


Day Low 47.01
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Fate Therapeutics Inc FATE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-4.60 -8.75% 48.00 20:00:01
Open Price Low Price High Price Close Price Prev Close
53.02 47.01 53.02 48.00 52.60
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
22,666 1,231,769 $ 48.51 $ 59,758,623 - 47.01 - 121.16
Last Trade Time Type Quantity Stock Price Currency
19:53:41 95 $ 48.65 USD


Draw Mode:

Fate Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.58B 95.49M 68.36M $ 31.43M $ - -2.08 -24.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -146.23k 1.20%

more financials information »

Fate Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical FATE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week53.3757.3847.0152.90769,727-5.37-10.06%
1 Month59.3665.1547.0155.10846,419-11.36-19.14%
3 Months70.1172.2947.0159.31914,265-22.11-31.54%
6 Months68.0097.4347.0171.57985,768-20.00-29.41%
1 Year60.94121.1647.0181.191,052,997-12.94-21.23%
3 Years15.98121.1611.0046.38924,53132.02200.38%
5 Years3.15121.162.4037.29738,21444.851,423.81%

Fate Therapeutics Description

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Your Recent History
Fate Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.